Staff Contact: Kara Amann-Kale or Keri Barclay
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee is hosting a meeting on Tuesday, Oct. 26, to review the Pfizer-BioNTech emergency use authorization request for administration of its COVID-19 vaccine in children ages five to 11. In anticipation of the FDA decision, the Centers for Disease Control and Prevention published the document, “Pediatric COVID-19 Vaccination Operational Planning Information,” which outlines known details and assumptions to inform planning of a COVID-19 vaccination program for children.